Comparative Cardiac Risks of Methylphenidate and Amphetamines in Treatment of ADHD

J Gordon Millichap

doi:10.15844/pedneurbriefs-23-8-6

Comparative Cardiac Risks of Methylphenidate and Amphetamines in Treatment of ADHD

Pediatric Neurology Briefs

Volume 23 (2009): Issue 8

By: J Gordon Millichap

Open Access

|Aug 2009

Abstract

The risk for adverse cardiac events in subjects between 3 and 20 years of age treated with methylphenidate or amphetamine salts for ADHD was determined in a retrospective study at University of Florida, Gainesville, FL.

References

Winterstein AG Gerhard T Shuster J Saidi A Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD Pediatrics 2009 Jul 124 1 e75 80 10.1542/peds.2008-3138 19564272
Open DOI Search in Google Scholar Back to article
Winterstein AG Gerhard T Shuster J Johnson M Zito JM Saidi A Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder Pediatrics 2007 Dec 120 6 e1494 501 10.1542/peds.2007-0675 18055666
Open DOI Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.15844/pedneurbriefs-23-8-6 | Journal eISSN: 2166-6482

Journal RSS Feed

Language: English

Page range: 61 - 62

Published on: Aug 1, 2009

Published by: Pediatric Neurology Briefs Publishers

In partnership with: Paradigm Publishing Services

Keywords:

Antidepressants,

Bronchodilators,

Congenital Anomalies

© 2009 J Gordon Millichap, published by Pediatric Neurology Briefs Publishers
This work is licensed under the Creative Commons Attribution 4.0 License.

Volume 23 (2009): Issue 8